<DOC>
	<DOCNO>NCT01425814</DOCNO>
	<brief_summary>The purpose study evaluate pharmacodynamics ( bronchodilation ) single dos inhale LAS100977 COPD patient .</brief_summary>
	<brief_title>Single Dose Study Assess Efficacy Safety 4 Doses LAS100977 Chronic Obstructive Pulmonary Disease ( COPD ) Population</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>1 . Males nonpregnant , nonlactating female age 40 old . 2 . Patients clinical diagnosis COPD , accord GOLD guideline stable airway obstruction . 3 . Patients postsalbutamol FEV1 equal great 30 % predict value le 80 % predict value 4 . Postsalbutamol FEV1/FVC &lt; 70 % screen visit . 5 . Predose FEV1 value first treatment period within range 80120 % FEV1 measure screen prior salbutamol inhalation . 6 . Current , excigarette smoker ( former ) smoke history least 10 packyears . 7 . Patients whose COPD symptoms time randomisation stable compare Screening visit , accord investigator 's medical judgment . 1 . History current diagnosis asthma . 2 . A respiratory tract infection COPD exacerbation six week prior screen visit . 3 . Patients hospitalise acute COPD exacerbation 3 month prior screen visit . 4 . Clinically significant respiratory condition COPD condition . 5 . Clinically significant cardiovascular condition . 6 . Patients unable properly use dry powder pMDI inhaler device unable perform acceptable spirometry . 7 . Clinically relevant abnormality laboratory , ECG parameters physical examination result screen evaluation investigator 's opinion , preclude study participation . 8 . Patients intend use concomitant medication permit protocol undergone require washout period particular prohibit medication .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>COPD</keyword>
</DOC>